FDA lawsuit in hand, Amarin plots a new Vascepa marketing strategy

Amarin ($AMRN) styled its lawsuit against the FDA looking to lift the restrictions in place on its marketing case for the prescription-strength fish oil Vascepa as a First Amendment issue regarding free speech. But it's clear that the company is looking to lift the reins that now prevent the physicians in its speaker bureau from touting more benefits than the ones allowed on a tightly controlled label. Blogger and Forbes contributor Larry Husten landed a copy of the letter, noting that the suit is more about marketing than free speech. "If we receive a judgement in our favor," writes Amarin, "we will move rapidly to deliver to you additional Company-approved training and updated promotional speaker materials related to the court's interpretation of free speech related to the ANCHOR results." Post

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.